Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus
説明
Current influenza vaccines are generally effective against highly similar (homologous) strains, but their effectiveness decreases markedly against antigenically mismatched (heterologous) strains. One way of developing a universal influenza vaccine with a broader spectrum of protection is to use appropriate vaccine adjuvants to improve a vaccine's effectiveness and change its immune properties. Oligodeoxynucleotides (ODNs) with unmethylated cytosine-phosphate-guanine (CpG) motifs (CpG ODNs), which are Toll-like-receptor 9 (TLR9) agonists, are among the most promising adjuvants and are already being used in humans. However, the development of novel delivery vehicles to improve adjuvant effects
収録刊行物
-
- Frontiers in Immunology
-
Frontiers in Immunology 10 3018-, 2020-01-09
Frontiers Media SA
- Tweet
キーワード
- Guanine
- Immunology
- Antibodies, Viral
- influenza virus
- Phosphates
- Cytosine
- Mice
- Influenza A Virus, H1N1 Subtype
- adjuvant
- interferon-α
- Orthomyxoviridae Infections
- vaccine
- Animals
- Vaccination
- RC581-607
- lipid nanoparticle
- Lipids
- CpG oligodeoxynucleotide
- Mice, Inbred C57BL
- Oligodeoxyribonucleotides
- Nanoparticles
- Immunization
- Immunologic diseases. Allergy
詳細情報 詳細情報について
-
- CRID
- 1361131644158414464
-
- ISSN
- 16643224
-
- PubMed
- 31998305
-
- 資料種別
- journal article
-
- データソース種別
-
- Crossref
- KAKEN
- OpenAIRE